Jin Medical International Ltd. (ZJYL) Ratios
Jin Medical International Ltd. Ratios
ZJYL's free cash flow for Q2 2026 was $-2.72M. For the 2026 fiscal year, ZJYL's free cash flow was decreased by $-1.79M and operating cash flow was $-934.42K. See a summary of the company’s cash flow.
| Ratios | Sep 25 | Sep 24 | Sep 23 | Sep 22 | Sep 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.86 | 2.50 | 3.49 | 3.31 | 2.47 |
| Quick Ratio | 1.65 | 2.08 | 2.83 | 2.11 | 1.57 |
| Cash Ratio | 0.31 | 0.47 | 0.78 | 0.84 | 0.47 |
| Solvency Ratio | 0.06 | 0.23 | 0.35 | 0.54 | 0.38 |
| Operating Cash Flow Ratio | 0.12 | -0.07 | 0.35 | 0.28 | 0.74 |
| Short-Term Operating Cash Flow Coverage | 0.15 | -0.11 | 0.76 | 0.00 | 0.00 |
| Net Current Asset Value | $ 20.35M | $ 25.57M | $ 22.19M | $ 13.20M | $ 11.55M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.35 | 0.25 | 0.13 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.64 | 0.40 | 0.17 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.39 | 0.29 | 0.15 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.80 | 1.59 | 1.37 | 1.37 | 1.56 |
| Debt Service Coverage Ratio | 0.04 | 0.28 | 0.67 | 0.00 | 314.21 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 277.23 |
| Debt to Market Cap | 0.21 | 0.03 | 0.02 | 0.00 | 0.00 |
| Interest Debt Per Share | 2.42 | 1.48 | 0.03 | 0.00 | 0.00 |
| Net Debt to EBITDA | 11.94 | 0.87 | -0.91 | -1.55 | -1.14 |
| Profitability Margins | |||||
| Gross Profit Margin | 29.22% | 40.43% | 34.23% | 32.30% | 30.64% |
| EBIT Margin | 2.94% | 15.48% | 14.47% | 14.29% | 13.92% |
| EBITDA Margin | 4.64% | 16.96% | 15.61% | 16.15% | 15.56% |
| Operating Profit Margin | 2.94% | 15.48% | 14.47% | 11.10% | 12.67% |
| Pretax Profit Margin | 7.71% | 17.80% | 16.25% | 14.29% | 13.87% |
| Net Profit Margin | 5.76% | 15.64% | 14.52% | 14.10% | 12.67% |
| Continuous Operations Profit Margin | 6.68% | 14.55% | 14.52% | 14.10% | 12.67% |
| Net Income Per EBT | 74.65% | 87.86% | 89.33% | 98.68% | 91.37% |
| EBT Per EBIT | 262.39% | 114.98% | 112.37% | 128.73% | 109.46% |
| Return on Assets (ROA) | 2.23% | 8.03% | 8.75% | 12.93% | 12.02% |
| Return on Equity (ROE) | 4.02% | 12.76% | 12.00% | 17.76% | 18.76% |
| Return on Capital Employed (ROCE) | 2.06% | 12.70% | 11.96% | 13.98% | 18.76% |
| Return on Invested Capital (ROIC) | 1.09% | 7.41% | 9.12% | 13.80% | 17.14% |
| Return on Tangible Assets | 2.28% | 8.23% | 8.79% | 13.03% | 12.12% |
| Earnings Yield | 1.35% | 0.87% | 1.69% | 5.04% | 2.47% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.04 | 2.68 | 2.33 | 4.51 | 3.47 |
| Payables Turnover | 4.50 | 4.65 | 3.84 | 3.16 | 2.69 |
| Inventory Turnover | 2.97 | 1.97 | 2.23 | 1.89 | 2.05 |
| Fixed Asset Turnover | 2.59 | 13.69 | 13.39 | 11.79 | 9.83 |
| Asset Turnover | 0.39 | 0.51 | 0.60 | 0.92 | 0.95 |
| Working Capital Turnover Ratio | 0.90 | 0.98 | 1.12 | 1.55 | 2.11 |
| Cash Conversion Cycle | 161.56 | 243.33 | 225.57 | 158.62 | 147.95 |
| Days of Sales Outstanding | 120.02 | 136.29 | 156.53 | 80.87 | 105.11 |
| Days of Inventory Outstanding | 122.72 | 185.58 | 163.98 | 193.31 | 178.44 |
| Days of Payables Outstanding | 81.18 | 78.54 | 94.94 | 115.57 | 135.61 |
| Operating Cycle | 242.74 | 321.87 | 320.51 | 274.19 | 283.55 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.37 | -0.15 | 0.02 | 0.01 | 0.02 |
| Free Cash Flow Per Share | -0.48 | -0.30 | 0.02 | 0.01 | 0.02 |
| Dividend Paid and CapEx Coverage Ratio | 0.44 | -1.07 | 27.26 | 39.35 | 136.27 |
| Capital Expenditure Coverage Ratio | 0.44 | -1.07 | 27.26 | 39.35 | 136.27 |
| Operating Cash Flow Coverage Ratio | 0.15 | -0.10 | 0.76 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.14 | -0.05 | 0.16 | 0.08 | 0.28 |
| Free Cash Flow Yield | -4.21% | -0.55% | 1.76% | 2.87% | 5.45% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 75.33 | 114.51 | 59.00 | 19.83 | 40.41 |
| Price-to-Sales (P/S) Ratio | 4.28 | 17.91 | 8.57 | 2.80 | 5.12 |
| Price-to-Book (P/B) Ratio | 2.98 | 14.61 | 7.08 | 3.52 | 7.58 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -23.74 | -180.53 | 56.75 | 34.84 | 18.34 |
| Price-to-Operating Cash Flow Ratio | 30.46 | -348.64 | 54.66 | 33.96 | 18.20 |
| Price-to-Earnings Growth (PEG) Ratio | -1.11 | 6.13 | -59.00 | 0.19 | 0.52 |
| Enterprise Value Multiple | 104.18 | 106.50 | 53.99 | 15.77 | 31.78 |
| Enterprise Value | 99.90M | 424.39M | 166.99M | 48.88M | 102.69M |
| EV to EBITDA | 104.18 | 106.50 | 53.99 | 15.77 | 31.78 |
| EV to Sales | 4.83 | 18.06 | 8.42 | 2.55 | 4.95 |
| EV to Free Cash Flow | -26.81 | -182.02 | 55.80 | 31.73 | 17.70 |
| EV to Operating Cash Flow | 34.40 | -351.52 | 53.76 | 30.92 | 17.57 |
| Tangible Book Value Per Share | 3.64 | 3.50 | 0.16 | 0.11 | 0.05 |
| Shareholders’ Equity Per Share | 3.79 | 3.68 | 0.17 | 0.11 | 0.05 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.13 | 0.18 | 0.11 | 0.01 | 0.09 |
| Revenue Per Share | 2.64 | 3.00 | 0.14 | 0.14 | 0.08 |
| Net Income Per Share | 0.15 | 0.47 | 0.02 | 0.02 | 0.01 |
| Tax Burden | 0.75 | 0.88 | 0.89 | 0.99 | 0.91 |
| Interest Burden | 2.62 | 1.15 | 1.12 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.08 | 0.06 | 0.08 | 0.10 | 0.08 |
| SG&A to Revenue | 0.19 | 0.19 | 0.10 | 0.09 | 0.08 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 2.10 | -0.35 | 1.08 | 0.58 | 2.22 |
Currency in USD
